Condition: Advanced Malignancies and Hepatic Impairment · Sponsor: Novartis Pharmaceuticals
The primary purpose of this study is to evaluate the impact of hepatic function on the pharmacokinetic (PK) profile of pelabresib in participants with advanced malignancies who have either hepatic impairment (HI) or normal liver function. To reduce participant burden and maximize benefit, the PK of pelabresib will be assessed at steady-state rather than after a single dose, avoiding treatment-free washout periods.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Bordeaux, France | Recruiting |
| Novartis Investigative Site | Saint-Herblain, France | Recruiting |
| Novartis Investigative Site | Candiolo, TO, Italy | Recruiting |
| Novartis Investigative Site | Pozuelo de Alarcón, Madrid, Spain | Recruiting |
| Novartis Investigative Site | Barcelona, Spain | Recruiting |
| Novartis Investigative Site | Madrid, Spain | Recruiting |
| Novartis Investigative Site | Madrid, Spain | Recruiting |
| Novartis Investigative Site | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07422610